Safety Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd., 3-1-98, Kasugade Naka, Konohanaku, Osaka 554-0022, Japan.
Toxicol Appl Pharmacol. 2012 Dec 15;265(3):351-9. doi: 10.1016/j.taap.2012.09.003. Epub 2012 Sep 12.
Clobazam (CLB) is known to increase hepatobiliary thyroxine (T4) clearance in Sprague-Dawley (SD) rats, which results in hypothyroidism followed by thyroid follicular cell hypertrophy. However, the mechanism of the acceleration of T4-clearance has not been fully investigated. In the present study, we tried to clarify the roles of hepatic UDP-glucronosyltransferase (UGT) isoenzymes (UGT1A and UGT2B) and efflux transporter (multidrug resistance-associated protein-2; MRP2) in the CLB-induced acceleration of T4-clearance using two mutant rat strains, UGT1A-deficient mutant (Gunn) and MRP2-deficient mutant (EHBR) rats, especially focusing on thyroid morphology, levels of circulating hormones (T4 and triiodothyronine (T3)) and thyroid-stimulating hormone (TSH), and mRNA or protein expressions of UGTs (Ugt1a1, Ugt1a6, and Ugt2b1/2) and MRP2 (Mrp). CLB induced thyroid morphological changes with increases in TSH in SD and Gunn rats, but not in EHBR rats. T4 was slightly decreased in SD and Gunn rats, and T3 was decreased in Gunn rats, whereas these hormones were maintained in EHBR rats. Hepatic Ugt1a1, Ugt1a6, Ugt2b1/2, and Mrp2 mRNAs were upregulated in SD rats. In Gunn rats, UGT1A mRNAs (Ugt1a1/6) and protein levels were quite low, but UGT2B mRNAs (Ugt2b1/2) and protein were prominently upregulated. In SD and Gunn rats, MRP2 mRNA and protein were upregulated to the same degree. These results suggest that MRP2 is an important contributor in development of the thyroid cellular hypertrophy in CLB-treated rats, and that UGT1A and UGT2B work in concert with MRP2 in the presence of MRP2 function to enable the effective elimination of thyroid hormones.
氯巴占(CLB)已知可增加 Sprague-Dawley(SD)大鼠的肝胆甲状腺素(T4)清除率,导致甲状腺功能减退症,随后出现甲状腺滤泡细胞肥大。然而,T4 清除率加速的机制尚未得到充分研究。在本研究中,我们试图使用两种突变大鼠品系,即 UGT1A 缺陷突变(Gunn)和 MRP2 缺陷突变(EHBR)大鼠,阐明肝 UDP-葡糖醛酸基转移酶(UGT)同工酶(UGT1A 和 UGT2B)和外排转运体(多药耐药相关蛋白-2;MRP2)在 CLB 诱导的 T4 清除加速中的作用,特别关注甲状腺形态、循环激素(T4 和三碘甲状腺原氨酸(T3))和促甲状腺激素(TSH)水平以及 UGTs(Ugt1a1、Ugt1a6 和 Ugt2b1/2)和 MRP2(Mrp)的 mRNA 或蛋白表达。CLB 诱导 SD 和 Gunn 大鼠的甲状腺形态变化,同时增加 TSH,但在 EHBR 大鼠中则没有。SD 和 Gunn 大鼠的 T4 略有下降,而 Gunn 大鼠的 T3 下降,而这些激素在 EHBR 大鼠中得以维持。SD 大鼠的肝 Ugt1a1、Ugt1a6、Ugt2b1/2 和 Mrp2 mRNAs 上调。在 Gunn 大鼠中,UGT1A mRNAs(Ugt1a1/6)和蛋白水平相当低,但 UGT2B mRNAs(Ugt2b1/2)和蛋白则显著上调。在 SD 和 Gunn 大鼠中,MRP2 mRNA 和蛋白上调程度相同。这些结果表明,MRP2 是 CLB 处理大鼠甲状腺细胞肥大发展的重要贡献者,并且在 MRP2 功能存在的情况下,UGT1A 和 UGT2B 与 MRP2 协同作用,以实现甲状腺激素的有效消除。